Literature DB >> 2149270

Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate.

A Noma1, S Maeda, M Okuno, A Abe, Y Muto.   

Abstract

The effect of low dose (600 mg/day) alpha-tocopheryl nicotinate on serum lipoprotein(a) (Lp(a] concentration was studied in 28 hyperlipidaemic patients. Serum lipids, lipoproteins and apolipoproteins, except for Lp(a), tended to increase after treatment. In particular, the changes in HDL-cholesterol and apo C-II levels were statistically significant. On the other hand, serum Lp(a) levels in all patients decreased significantly after 2 months of treatment. Furthermore, no difference between before and after treatment was observed in the group with initial Lp(a) levels less than 18 mg/dl, whereas Lp(a) concentrations decreased significantly after treatment in the group with levels greater than or equal to 18 mg/dl. The effects of probucol and alpha-tocopheryl nicotinate on serum Lp(a), total cholesterol and HDL-cholesterol were entirely different. Possible mechanisms of alpha-tocopheryl nicotinate on serum Lp(a) and lipoprotein metabolism are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149270     DOI: 10.1016/0021-9150(90)90093-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

2.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

3.  Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia.

Authors:  P Schwandt; R Elsässer; C Schmidt; B Gertz; M Heil; J Augustin; K Seibel
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Vitamin E Nicotinate.

Authors:  Kimbell R Duncan; Yuichiro J Suzuki
Journal:  Antioxidants (Basel)       Date:  2017-03-13

Review 5.  Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

Authors:  Maria Francesca Greco; Cesare R Sirtori; Alberto Corsini; Marat Ezhov; Tiziana Sampietro; Massimiliano Ruscica
Journal:  J Clin Med       Date:  2020-07-03       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.